209 related articles for article (PubMed ID: 28548891)
21. Treatment with IL-27 attenuates experimental colitis through the suppression of the development of IL-17-producing T helper cells.
Sasaoka T; Ito M; Yamashita J; Nakajima K; Tanaka I; Narita M; Hara Y; Hada K; Takahashi M; Ohno Y; Matsuo T; Kaneshiro Y; Tanaka H; Kaneko K
Am J Physiol Gastrointest Liver Physiol; 2011 Apr; 300(4):G568-76. PubMed ID: 21193526
[TBL] [Abstract][Full Text] [Related]
22. Interplay between T(h)1 and T(h)17 effector T-cell pathways in the pathogenesis of spontaneous colitis and colon cancer in the Gαi2-deficient mouse.
Götlind YY; Fritsch Fredin M; Kumawat AK; Strid H; Willén R; Rangel I; Bland PW; Hörnquist EH
Int Immunol; 2013 Jan; 25(1):35-44. PubMed ID: 22962436
[TBL] [Abstract][Full Text] [Related]
23. Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B.
Liu QQ; Wang HL; Chen K; Wang SB; Xu Y; Ye Q; Sun YW
J Dig Dis; 2016 Feb; 17(2):104-12. PubMed ID: 26718746
[TBL] [Abstract][Full Text] [Related]
24. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
25. Endoscopic findings of ipilimumab-induced colitis.
Satoh T; Ohno K; Kurokami T
Dig Endosc; 2017 May; 29(3):388-389. PubMed ID: 28128877
[No Abstract] [Full Text] [Related]
26. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
[No Abstract] [Full Text] [Related]
27. Toll-like receptor 2 monoclonal antibody or/and Toll-like receptor 4 monoclonal antibody increase counts of Lactobacilli and Bifidobacteria in dextran sulfate sodium-induced colitis in mice.
Dong L; Li J; Liu Y; Yue W; Luo X
J Gastroenterol Hepatol; 2012 Jan; 27(1):110-9. PubMed ID: 21722182
[TBL] [Abstract][Full Text] [Related]
28. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.
Minor DR; Chin K; Kashani-Sabet M
Cancer Biother Radiopharm; 2009 Jun; 24(3):321-5. PubMed ID: 19538054
[TBL] [Abstract][Full Text] [Related]
29. Dextran sulfate sodium-induced acute experimental colitis in C57BL/6 mice is mitigated by selenium.
Sang L; Chang B; Zhu J; Yang F; Li Y; Jiang X; Sun X; Lu C; Wang D
Int Immunopharmacol; 2016 Oct; 39():359-368. PubMed ID: 27533281
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital.
Rastogi P; Sultan M; Charabaty AJ; Atkins MB; Mattar MC
World J Gastroenterol; 2015 Apr; 21(14):4373-8. PubMed ID: 25892889
[TBL] [Abstract][Full Text] [Related]
31. TIR-domain-containing adapter-inducing interferon-β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis.
Kanagavelu S; Flores C; Termini JM; Riveron R; Romero L; Chung K; Ruiz J; Hyun J; Yuan X; Dagvadorj J; Fukata M
Mucosal Immunol; 2015 Mar; 8(2):296-306. PubMed ID: 25073675
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
33. Blockade of IL-6 signal exacerbates acute inflammatory bowel disease via inhibiting IL-17 producing in activated CD4+ Th17 population.
Zhang SJ; Wang L; Ming L; Guo XB; Wang HM; Li XW; Li L
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3291-5. PubMed ID: 24379058
[TBL] [Abstract][Full Text] [Related]
34. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.
Coutzac C; Adam J; Soularue E; Collins M; Racine A; Mussini C; Boselli L; Kamsukom N; Mateus C; Charrier M; Cassard L; Planchard D; Ribrag V; Fizazi K; Loriot Y; Lepage P; Scoazec JY; Robert C; Carbonnel F; Chaput N
J Crohns Colitis; 2017 Oct; 11(10):1238-1246. PubMed ID: 28967957
[TBL] [Abstract][Full Text] [Related]
35. Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies.
Chen JH; Pezhouh MK; Lauwers GY; Masia R
Am J Surg Pathol; 2017 May; 41(5):643-654. PubMed ID: 28296676
[TBL] [Abstract][Full Text] [Related]
36. Chitosan oligosaccharide as potential therapy of inflammatory bowel disease: therapeutic efficacy and possible mechanisms of action.
Yousef M; Pichyangkura R; Soodvilai S; Chatsudthipong V; Muanprasat C
Pharmacol Res; 2012 Jul; 66(1):66-79. PubMed ID: 22475725
[TBL] [Abstract][Full Text] [Related]
37. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
38. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
39. IL-33 alleviates DSS-induced chronic colitis in C57BL/6 mice colon lamina propria by suppressing Th17 cell response as well as Th1 cell response.
Zhu J; Wang Y; Yang F; Sang L; Zhai J; Li S; Li Y; Wang D; Lu C; Sun X
Int Immunopharmacol; 2015 Dec; 29(2):846-853. PubMed ID: 26359542
[TBL] [Abstract][Full Text] [Related]
40. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P; Hamid O; O'Day S
Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
